Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0831 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0831 | DRUG | - |
Inclusion Criteria: * Not tolerating current ART regime laboratory status is stable * Able to take oral liquid medications but have difficulty swallowing capsules * Weigh at least 10 kg (22 lbs) Exclusion Criteria: * Has had more than 2 episodes of moderate to severe diarrhea or vomiting lasting ...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
MK0831 is an investigational small molecule being developed for the treatment of HIV Infections. It is currently in Phase 3 clinical development, though the only listed trial is a completed expanded access program, meaning it remains under investigation and is not yet approved.
MK0831 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical research on this investigational small molecule for HIV Infections.
MK0831 is in Phase 3 clinical development for HIV Infections. The single trial listed is a completed Phase 3 expanded access program, and the drug remains investigational, meaning it has not been approved by regulatory authorities.
MK0831 has one completed clinical trial, NCT00543530, titled "Pediatric Expanded Access Program-Oral Solution (0831-908)." This Phase 3 study enrolled pediatric patients aged 3 years and older with HIV Infections and was an uncontrolled, open-label expanded access program.
MK0831 is not FDA approved. It is an investigational drug in Phase 3 clinical development for HIV Infections. The only listed trial is a completed expanded access program, which does not constitute approval, and the drug remains under clinical investigation.